We have a clinical trial collaboration agreement with Bristol Myers Squibb for our bacterial consortia drug candidate for Immune-Oncology VE800.
Vedanta has been awarded two research grants from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the development of VE303, the Company’s product candidate for the treatment of high-risk C. difficile infection (CDI) and VE707, Vedanta’s preclinical discovery program for the prevention of infection and recurrence of several MDROs, including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE).
We have entered into a clinical translational medicine collaboration with Leiden University Medical Center that focuses on collection of samples from healthy donors as well as clinical data and/or interventional studies of fecal transplantation in a variety of indications.
We have entered into a translational collaboration with CHUM focused on understanding the microbiome of cancer patients being treated with checkpoint inhibitors.
We have entered into a translational collaboration with the NYU Langone Medical Center focused on developing novel microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.
We have entered into a translational collaboration with Hôpital Raymond Poincaré focused on the development of microbiome-based therapeutics for multi-drug resistant organisms.
We have entered into a translational medicine collaboration with VHIO to understand how the microbiome of cancer patients influences responses to immune checkpoint inhibitors.
Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards.
How Our Proprietary Discovery Platform Works
